|
C15ORF33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.43849426498855E-15 |
| Normal-vs-Stage2 |
7.48139999950936E-08 |
| Normal-vs-Stage3 |
4.70734562441066E-14 |
| Normal-vs-Stage4 |
2.66786592817425E-13 |
| Stage1-vs-Stage2 |
6.962200E-01 |
| Stage1-vs-Stage3 |
1.265600E-01 |
| Stage1-vs-Stage4 |
8.197100E-03 |
| Stage2-vs-Stage3 |
1.594830E-01 |
| Stage2-vs-Stage4 |
2.432000E-02 |
| Stage3-vs-Stage4 |
2.879600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.13566966731105E-12 |
| Normal-vs-AfricanAmerican |
2.590300E-04 |
| Normal-vs-Asian |
1.72320000046966E-07 |
| Caucasian-vs-AfricanAmerican |
1.523190E-01 |
| Caucasian-vs-Asian |
3.736000E-01 |
| AfricanAmerican-vs-Asian |
5.826400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.37507799486048E-14 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.323400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49700252194407E-11 |
| Normal-vs-Age(41-60Yrs) |
1.15651932475203E-12 |
| Normal-vs-Age(61-80Yrs) |
2.37010411296978E-12 |
| Normal-vs-Age(81-100Yrs) |
7.170100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.783400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.707400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.212600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.949440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.152600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.614000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.48509999999369E-05 |
| Classical-VS-Follicular |
7.246300E-02 |
| Classical-VS-Other |
6.698200E-01 |
| Classical-VS-Normal |
8.23070500644008E-11 |
| Tall-VS-Follicular |
1.94009999998634E-06 |
| Tall-VS-Other |
1.734170E-01 |
| Tall-VS-Normal |
3.10862446895044E-15 |
| Follicular-VS-Other |
8.340800E-01 |
| Follicular-VS-Normal |
1.65250000017103E-07 |
| Other-VS-Normal |
1.375680E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.703803764741E-11 |
| Normal-vs-N1 |
1.47326595367758E-13 |
| N0-vs-N1 |
1.737630E-03 |
|
|
